PMID- 38224276
OWN - NLM
STAT- MEDLINE
DCOM- 20240116
LR  - 20240116
IS  - 1110-4902 (Print)
VI  - 31
IP  - 1
DP  - 2024 Jan
TI  - The role of urinary biomarker monocyte chemoattractant protein (MCP-1) in 
      correlation with different histopathological classes of lupus nephritis in 
      Egyptian patients.
PG  - 116-123
AB  - Lupus nephritis (LN) affects almost two-thirds of systemic lupus erythematosus 
      (SLE) patients. Renal biopsy is the gold standard for the diagnosis of LN. 
      However, repeated biopsies are not always performed in clinical practice, and 
      they carry some risk. Therefore, minimally invasive techniques, as urinary 
      biomarkers, are promising tools for the diagnosis and monitoring of SLE. Previous 
      studies evaluated urinary monocyte chemoattractant protein-1 (MCP-1) in patients 
      with SLE, reported higher levels of urinary MCP-1 in patients with active LN than 
      non-active LN. Other studies reported higher levels of urinary MCP-1 in LN 
      patients with proliferative forms (III and IV). This study aimed to evaluate 
      urinary MCP-1 as a noninvasive diagnostic biomarker tool for LN, and to determine 
      its association with different LN histopathological stages and chronicity 
      indices. The study included 40 SLE patients with biopsy-proven LN class II, III, 
      IV or V, and 20 patients with inactive LN as a control group. In LN active 
      patients, the mean creatinine was 1.71 +/- 0.55 mg/dl, and 0.84 +/- 0.10 mg/dl in the 
      control group. The mean MCP-1 level was 618.4 +/- 294.2 ng/l in active LN patients 
      and 120.05 +/- 87.53 ng/l in inactive LN patients. The receiver operating 
      characteristic (ROC) curve analysis indicated a better diagnostic performance of 
      MCP-1 than conventional biomarkers. At area under the curve of 0.990, the best 
      cut-off level was >245 ng/L (sensitivity 97.5 %, Specificity 95 %). In 
      conclusion, urinary MCP-1 distinguished active LN from inactive renal disease. It 
      can be proposed as a good noninvasive diagnostic biomarker with a high 
      sensitivity and specificity for detection of LN activity..
CI  - Copyright(c) by the Egyptian Association of Immunologists.
FAU - El-Shinnawy, Howayda
AU  - El-Shinnawy H
AD  - Department of Internal Medicine, Nephrology Unit, Faculty of Medicine, Ain Shams 
      University, Cairo 11566, Egypt.
FAU - Mahmoud, Osama
AU  - Mahmoud O
AD  - Department of Internal Medicine, Nephrology Unit, Faculty of Medicine, Ain Shams 
      University, Cairo 11566, Egypt.
FAU - Abdelmohsen, Waleed
AU  - Abdelmohsen W
AD  - Department of Internal Medicine, Nephrology Unit, Faculty of Medicine, Ain Shams 
      University, Cairo 11566, Egypt.
FAU - Ahmed, Amr
AU  - Ahmed A
AD  - Department of Internal Medicine, Nephrology Unit, Faculty of Medicine, Ain Shams 
      University, Cairo 11566, Egypt.
FAU - Khedr, Lamis
AU  - Khedr L
AD  - Department of Internal Medicine, Nephrology Unit, Faculty of Medicine, Ain Shams 
      University, Cairo 11566, Egypt.
LA  - eng
PT  - Journal Article
PL  - Egypt
TA  - Egypt J Immunol
JT  - The Egyptian journal of immunology
JID - 9816016
RN  - 0 (Monocyte Chemoattractant Proteins)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - *Lupus Nephritis/diagnosis
MH  - Monocyte Chemoattractant Proteins
MH  - Egypt
MH  - *Lupus Erythematosus, Systemic/diagnosis
MH  - Biomarkers
EDAT- 2024/01/15 12:43
MHDA- 2024/01/16 06:41
CRDT- 2024/01/15 09:43
PHST- 2024/01/16 06:41 [medline]
PHST- 2024/01/15 12:43 [pubmed]
PHST- 2024/01/15 09:43 [entrez]
PST - ppublish
SO  - Egypt J Immunol. 2024 Jan;31(1):116-123.